Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19580150 | 0.99 | ACP1 (0.35) | ACP1HSD11B1NPY5RTRPA1HDAC3 | |
| SCHEMBL2448959 | 0.87 | TRPM8 (0.37) | ACP1HSD11B1NPY5RTRPA1CYP1A2 | |
| SCHEMBL2448004 | 0.85 | HSD11B1 (0.37) | ACP1HSD11B1TRPA1CYP1A2CYP2C19 | |
| SCHEMBL2448009 | 0.85 | HSD11B1 (0.37) | ACP1HSD11B1TRPA1CYP1A2CYP2C19 | |
| SCHEMBL15589707 | 0.84 | TRPA1 (0.36) | ACP1NPY5RTRPA1F2RL3 | |
| SCHEMBL15589691 | 0.84 | NPY5R (0.53) | ACP1NPY5RCYP1A2 | |
| SCHEMBL11899420 | 0.83 | TRPA1 (0.47) | HSD11B1NPY5RTRPA1HDAC3HDAC7 | |
| Hydrochloric Acid SCHEMBL11899873 | 0.83 | TRPA1 (0.46) | HSD11B1NPY5RTRPA1HDAC3HDAC7 | |
| SCHEMBL2479895 | 0.82 | PTGES (0.40) | ACP1HSD11B1TRPA1HDAC3HDAC7 | |
| SCHEMBL15754200 | 0.82 | CYP1A2 (0.38) | ACP1NPY5RTRPA1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542552-B1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-15 | — | — | EP | disclosed |
| US-9718820-B2 | Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-01 | — | — | US | disclosed |
| US-9409915-B2 | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-09 | — | — | US | disclosed |
| US-20150158875-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | US | disclosed |
| US-9023846-B2 | Substituted AZA-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-05 | — | — | US | disclosed |
| US-20140155395-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-05 | — | — | US | disclosed |
| US-8680098-B2 | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-25 | — | — | US | disclosed |
| EP-2542552-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011109587-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-09 | — | — | WO | disclosed |
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158875-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | ACP1 2784/4885HSD11B1 4771/4885NPY5R 1240/4885 |
| US-20140155395-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | ACP1 2784/4885HSD11B1 4771/4885NPY5R 1240/4885 |
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | ACP1 2784/4885HSD11B1 4771/4885NPY5R 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.